vaccination

In this retrospective cohort study the authors aimed to evaluate overall and variant-specific effectiveness of BNT162b2 against SARS-CoV-2 infections and COVID-19-related hospital admissions by time since vaccination among members of a large US healthcare system.

In this retrospective surveillance study, the authors provide estimates of the number of SARS-CoV-2 infections and COVID-19-related admissions to hospital (ie, hospitalisations) and deaths averted by the nationwide vaccination campaign.

In this article the authors retrospectively reviewed data obtained from December 20, 2020, to May 31, 2021, regarding all cases of myocarditis and categorized the information using the Brighton Collaboration definition.

In this article the authors searched the database of Clalit Health Services, the largest health care organization (HCO) in Israel, for diagnoses of myocarditis in patients who had received at least one dose of the BNT162b2 mRNA vaccine (Pfizer–BioNTech).

Study of data from the Israeli Ministry of Health database regarding 1,137,804 persons who were 60 years of age or older and had been fully vaccinated at least 5 months earlier.

The authors investigated the safety, vaccine efficacy, and immunogenicity of two doses of AZD1222 as compared with placebo in preventing the onset of symptomatic and severe COVID-19 15 days or more after the second dose in adults.

In this article the authors used a matched test-negative, case–control study design to estimate vaccine effectiveness against any SARS-CoV-2 infection and against any severe, critical, or fatal case of COVID-19, from January 1 to September 5, 2021.

In this article the authors conducted a 6-month longitudinal prospective study involving vaccinated health care workers who were tested monthly for the presence of anti-spike IgG and neutralizing antibodies.

This Self-controlled case series study using national data on COVID-19 vaccination and hospital admissions.

In this study the authors investigated the effect of vaccination of health care workers in Scotland on the risk of coronavirus disease 2019 (COVID-19) among members of their households.

In this ongoing trial, the authors randomly assigned 44,165 participants aged 16 or older and 2,264 participants aged 12-15 to receive two 30-μg doses, at 21 days apart, of BNT162b2 or placebo.

In this article the authors review neurological conditions seen in the context of prior vaccinations and the current data to date on select COVID-19 vaccines.

In this article the authors investigated induction of antigen-specific antibody, B cell and T cell responses longitudinally in patients with multiple sclerosis (MS) on anti-CD20 antibody monotherapy (n = 20) compared with healthy controls (n = 10) after BNT162b2 or mRNA-1273 mRNA vaccination.

In this article the authors assessed the persistence of immunogenicity after a single dose of ChAdOx1 nCoV-19 (AZD1222), immunity after an extended interval (44–45 weeks) between the first and second dose, and response to a third dose as a booster given 28–38 weeks after the second dose.

In this article the authors used data from the largest health care organization in Israel to evaluate the safety of the BNT162b2 mRNA vaccine.